Objective
Venous thromboembolism (VTE) is a frequent and life-threatening disease. In 50% of cases, VTE occurs in the absence of any major risk factors (unprovoked VTE). In these patients, when anticoagulation is stopped after 3 months of anticoagulation, more than 35% will develop recurrent VTE. Consequently, international guidelines recommend to treat these patients “indefinitely”. However, such practice exposes them to a substantial increase risk of bleeding. Nevertheless, after several years of anticoagulation in all patients with unprovoked VTE, the risk of anticoagulant-related bleeding is expected to exceed the risk of recurrent VTE after stopping treatment. In addition, extending anticoagulation indefinitely in all patients with unprovoked VTE exposes 65% of patients to an unjustified high risk of bleeding, who would never have experienced recurrent VTE after stopping treatment.
In this setting, optimal duration and management of anticoagulation remains a pivotal and unresolved challenging issue which has the potential to markedly improve long-term prognosis of unprovoked VTE. Based on quantitative and qualitative approaches, MORPHEUS will for the first time integrate (i) clinical, laboratory and imaging biomarkers (personalized medicine) and (ii) socio-anthropological markers (patient-centred model) into sets of prediction rules for optimizing anticoagulant management integrated in a shared decision-making process. The ultimate goal of the European “MORPHEUS” project will be to develop and validate a time-dependent multi-component tool integrated in a shared decision-making process regarding anticoagulant treatment duration in patients with unprovoked VTE. The whole MORPHEUS program, leaded by a consortium of outstanding European researchers in the field of VTE, will constitute a major breakthrough compared with the present standard of care in patients with unprovoked VTE with major scientific, public health, economic, and societal impacts.
Fields of science
Keywords
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
29609 Brest
France
See on map
Participants (15)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
29238 BREST
See on map
75654 Paris
See on map
75006 Paris
See on map
75014 Paris
See on map
28046 MADRID
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
28034 Madrid
See on map
100 44 Stockholm
See on map
33000 Bordeaux
See on map
55131 Mainz
See on map
28006 Madrid
See on map
2333 ZA Leiden
See on map
1165 Kobenhavn
See on map
3032 AC Rotterdam
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
02 091 Warszawa
See on map
7100 Vejle
See on map
Partners (1)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1211 Geneve
See on map